Bankers and underwriters have plenty to be thankful for. Bond issuance is running hot, this year’s IPO count is up (at least ...

Within five business days, Alkermes can negotiate with Avadel to amend its original takeover offer to beat Lundbeck.

Strong clinical data doesn’t just move share prices – it can unlock lucrative global licensing deals for ASX-listed ...

Now, it’s worth noting Stock Advisor’s total average return is 1,035% — a market-crushing outperformance compared to 191 % ...

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

Paul Sweeney harnesses the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Pfizer has officially closed on its $10 billion purchase of obesity drug maker Metsera. So what does everyone think of the ...

Pfizer officially buys Metsera; Zealand halts early obesity drug; ESPN, Zepbound and the twilight of the middleman.

An announcement from Metsera, Inc. ( ($MTSR) ) is now available. Metsera, Inc. announced the completion of its merger, effective November 13, ...

US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to ...

Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...